Skip to content
value.today

Aktis Oncology, Inc.

AKTS
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
79
As of December 31, 2025
SEC filing

Aktis Oncology, Inc. in brief

Aktis Oncology, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It employs about 79 people. Its shares trade under the symbol AKTS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Aktis Oncology, Inc.

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type, yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting.

From the company's annual report filed with the US SEC: read the report

Aktis Oncology, Inc. timeline

2 events, 2024–2026
  1. 2024
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 9 January 2026; shares registered for exchange trading on 7 January 2026.

Events of Aktis Oncology, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue $1M, net income $-15M$1MMar ’25Three months to Jun 2025: revenue $2M, net income $-18M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $-16M$2MSep ’25Three months to Mar 2026: revenue $3M, net income $-18M$3MMar ’26Three months to Jun 2026: revenue $3M, net income $-24M$3MJun ’26Three months to Sep 2026: revenue $4M, net income $-30M$4MSep ’26

Latest quarter to Sep 2026: revenue $4M (+146.8% on a year earlier), net income $-30M.

SEC filings

Official filings of Aktis Oncology, Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$265 M
Total liabilities
$78 M
Total equity
$-146 M

As of December-2025

Top 100 institutional investors in Aktis Oncology, Inc.#

As of Sep 30, 2026
125 institutions held 36.8 M shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Aktis Oncology, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1MPM Bioimpact LLC4,835,8720 (0.00%)$94 MNov 16, 2026
2EcoR1 Capital, LLC4,824,4690 (0.00%)$94 MNov 16, 2026
3Blue Owl Capital Holdings LP3,343,827+273,608 (+8.91%)$65 MNov 13, 2026
4T. Rowe Price Investment Management, Inc.3,333,026+1,281,579 (+62.47%)$65 MNov 16, 2026
5BlackRock, Inc.2,780,745+502,387 (+22.05%)$54 MNov 13, 2026
6RTW Investments, LP1,592,0430 (0.00%)$31 MNov 16, 2026
7Wellington Management Group LLP1,471,969-494,275 (-25.14%)$29 MNov 16, 2026
8Price T Rowe Associates Inc /MD/1,184,617+421,118 (+55.16%)$23 MNov 16, 2026
9Vanguard Capital Management LLC1,180,925+363,850 (+44.53%)$23 MNov 13, 2026
10Eventide Asset Management, LLC1,065,000+558,000 (+110.06%)$21 MNov 13, 2026
11State Street Corp1,050,480+566,470 (+117.04%)$20 MNov 12, 2026
12Baker Bros. Advisors LP996,3510 (0.00%)$19 MNov 16, 2026
13Merck & Co., Inc.952,8440 (0.00%)$19 MNov 13, 2026
14ArrowMark Colorado Holdings LLC852,159+606,287 (+246.59%)$17 MNov 16, 2026
15Octagon Capital Advisors LP713,000-247,847 (-25.79%)$14 MNov 16, 2026
16Geode Capital Management, LLC690,427+169,690 (+32.59%)$13 MNov 6, 2026
17Avidity Partners Management LP484,2000 (0.00%)$9 MNov 16, 2026
18Two Sigma Investments, LP436,467+405,553 (+1311.87%)$8 MNov 16, 2026
19a16z Capital Management, L.L.C.415,0000 (0.00%)$8 MNov 16, 2026
20Affinity Asset Advisors, LLC350,000New$7 MNov 13, 2026
21Alyeska Investment Group, L.P.290,0000 (0.00%)$6 MNov 16, 2026
22Northern Trust Corp236,638+56,063 (+31.05%)$5 MNov 16, 2026
23Charles Schwab Investment Management Inc230,818+63,976 (+38.35%)$4 MNov 16, 2026
24TD Asset Management Inc203,494+97,592 (+92.15%)$4 MNov 13, 2026
25Vanguard Portfolio Management LLC198,386+53,166 (+36.61%)$4 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Aktis Oncology, Inc.
#InstitutionShares heldChange (shares)ValueFiled
26Millennium Management LLC192,728New$4 MNov 16, 2026
27Vanguard Fiduciary Trust Co183,780+49,946 (+37.32%)$4 MNov 13, 2026
28Woodline Partners LP172,608+72,608 (+72.61%)$3 MNov 16, 2026
29Mirador Capital Partners LP133,558+93,434 (+232.86%)$3 MOct 9, 2026
30TCG Crossover Management, LLC133,457-563,103 (-80.84%)$3 MNov 16, 2026
31Point72 Asset Management, L.P.132,886New$3 MNov 16, 2026
32Citadel Advisors LLC115,857+90,320 (+353.68%)$2 MNov 16, 2026
33Jump Financial, LLC112,187+79,408 (+242.25%)$2 MNov 13, 2026
34UBS Group AG110,322+10,362 (+10.37%)$2 MNov 10, 2026
35Quantinno Capital Management LP109,075+62,188 (+132.63%)$2 MNov 13, 2026
36Bank Of America Corp /de/106,894+34,059 (+46.76%)$2 MNov 16, 2026
37Morgan Stanley91,569+28,933 (+46.19%)$2 MNov 13, 2026
38Goldman Sachs Group Inc85,135+63,857 (+300.11%)$2 MNov 16, 2026
39Manufacturers Life Insurance Company, The80,065+32,021 (+66.65%)$2 MNov 13, 2026
40Polen Capital Management LLC72,795+9,281 (+14.61%)$1 MNov 13, 2026
41BNP Paribas Financial Markets70,816+67,536 (+2059.02%)$1 MNov 12, 2026
42Marshall Wace, LLP69,158New$1 MNov 13, 2026
43Bank of New York Mellon Corp67,042+17,792 (+36.13%)$1 MNov 5, 2026
44Barclays PLC66,716-84,980 (-56.02%)$1 MNov 6, 2026
45Tidal Investments LLC65,989+8,930 (+15.65%)$1 MNov 13, 2026
46Quadrature Capital Ltd61,695New$1 MNov 13, 2026
47Nuveen, LLC60,357+10,541 (+21.16%)$1 MNov 10, 2026
48HRT Financial LP57,873New$1 MNov 13, 2026
49Trexquant Investment LP54,037New$1 MNov 16, 2026
50XTX Topco Ltd51,513New$1 MNov 16, 2026
51AQR Capital Management LLC37,478-10,645 (-22.12%)$1 MNov 16, 2026
52Ameriprise Financial Inc36,059+16,059 (+80.30%)$1 MNov 16, 2026
53Sofinnova Investments, Inc.31,605-831 (-2.56%)$1 MNov 16, 2026
54Rhumbline Advisers31,196+4,251 (+15.78%)$1 MNov 10, 2026
55Renaissance Technologies LLC30,539-64,861 (-67.99%)$1 MNov 12, 2026
56Raymond James Financial Inc30,449-20,015 (-39.66%)$1 MNov 12, 2026
57Weiss Asset Management LP30,422New$1 MNov 16, 2026
58Ghisallo Capital Management LLC25,0000 (0.00%)$0 MNov 16, 2026
59Seven Grand Managers, LLC25,0000 (0.00%)$0 MNov 16, 2026
60Tudor Investment Corp Et Al24,980+3,578 (+16.72%)$0 MNov 16, 2026
61Deutsche Bank AG\24,350+3,328 (+15.83%)$0 MNov 6, 2026
62Algert Global LLC22,820New$0 MNov 17, 2026
63Rafferty Asset Management, LLC22,132New$0 MNov 13, 2026
64Alliancebernstein L.P.17,900New$0 MNov 16, 2026
65MetLife Investment Management, LLC16,542+3,548 (+27.30%)$0 MNov 16, 2026
66MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.15,393+5,624 (+57.57%)$0 MNov 16, 2026
67NLB Skladi, upravljanje premozenja, d.o.o.15,000New$0 MOct 22, 2026
68Gsa Capital Partners LLP14,946New$0 MNov 16, 2026
69Virtus Investment Advisers, LLC14,470-450 (-3.02%)$0 MNov 12, 2026
70Jpmorgan Chase & Co14,129+5,294 (+59.92%)$0 MNov 12, 2026
71Invesco Ltd.14,115-793 (-5.32%)$0 MNov 12, 2026
72American Century Companies Inc13,895New$0 MNov 12, 2026
73State Of Wisconsin Investment Board11,974New$0 MNov 16, 2026
74Wells Fargo & Company/mn11,261-16,398 (-59.29%)$0 MNov 16, 2026
75Vanguard Global Advisers, LLC10,192+3,306 (+48.01%)$0 MNov 13, 2026
76Mercer Global Advisors Inc /adv10,115New$0 MNov 16, 2026
77Caprock Group, LLC10,000+92 (+0.93%)$0 MNov 17, 2026
78Citigroup Inc9,756-3,421 (-25.96%)$0 MNov 4, 2026
79Russell Investments Group, Ltd.8,391+637 (+8.22%)$0 MNov 6, 2026
80Police & Firemen's Retirement System of New Jersey7,551+2,021 (+36.55%)$0 MNov 9, 2026
81New York State Common Retirement Fund7,5000 (0.00%)$0 MNov 17, 2026
82Lanark Financial, Inc.5,567+209 (+3.90%)$0 MOct 26, 2026
83Aquatic Capital Management LLC3,977New$0 MNov 16, 2026
84FMR LLC3,398-282,233 (-98.81%)$0 MNov 10, 2026
85Legal & General Group Plc2,689+627 (+30.41%)$0 MNov 16, 2026
86Ameritas Investment Partners, Inc.2,550+625 (+32.47%)$0 MNov 13, 2026
87Strs Ohio2,200-900 (-29.03%)$0 MOct 30, 2026
88Osaic Holdings, Inc.1,673New$0 MNov 12, 2026
89Royal Bank Of Canada1,610+813 (+102.01%)$0 MNov 16, 2026
90Jones Financial Companies Lllp1,600New$0 MNov 13, 2026
91Global Retirement Partners, LLC1,537+1,142 (+289.11%)$0 MNov 10, 2026
92Silver Grove Financial Group, Inc.1,449New$0 MNov 5, 2026
93Rockefeller Capital Management L.P.1,422+1,025 (+258.19%)$0 MNov 13, 2026
94GK Wealth Management LLC1,350New$0 MOct 9, 2026
95Tower Research Capital LLC (TRC)1,312-956 (-42.15%)$0 MNov 16, 2026
96Sterling Capital Management LLC823+639 (+347.28%)$0 MOct 22, 2026
97Aster Capital Management (DIFC) Ltd748New$0 MNov 12, 2026
98State of Wyoming653-332 (-33.71%)$0 MOct 28, 2026
99Arax Advisory Partners452+67 (+17.40%)$0 MNov 12, 2026
100Quarry LP445+411 (+1208.82%)$0 MNov 16, 2026

All 125 institutional investors, with who bought and sold →

Superinvestors holding Aktis Oncology, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Aktis Oncology, Inc.#

95 funds hold shares worth $198 M. Since their previous reports 64 added shares and 13 sold, buying $1 M net.
Mutual funds holding Aktis Oncology, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Health Care FundWellington Management Company LLP1.46 M$32 M—0.08%−28%Jul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc.676,577$22 M—0.23%+10%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.585,135$19 M—<0.01%−3.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors545,302$18 M—0.02%+18%Jun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC507,000$16 M—0.91%no changeJun 30, 2026
🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc.358,947$12 M—0.23%+12%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.333,745$11 M—0.09%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.209,816$7 M—<0.01%+0.1%Jun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.196,735$6 M—0.04%−0.0%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC283,355$6 M—0.11%−26%May 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC266,503$6 M—0.09%no changeMay 29, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.163,403$5 M—0.05%−20%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC232,435$5 M—0.02%+15%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors133,328$4 M—0.03%+56%Jun 30, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC105,570$3 M—1.2%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.105,593$2 M—0.01%+2571%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC97,084$2 M—<0.01%newMay 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors59,825$2 M—0.01%−25%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC58,563$2 M—0.18%no changeJun 30, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.88,457$2 M—<0.01%newMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC39,040$1 M—0.02%+19%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.51,557$1 M—0.02%+14%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC41,318$1 M—<0.01%newMay 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC23,229$1 M—0.13%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC22,979$1 M—0.02%+13%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.20,013$1 M—0.09%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC28,152$1 M—0.02%+15%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC28,570$1 M—<0.01%+94%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC28,478$1 M—<0.01%newMay 31, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC16,038$1 M—0.14%no changeJun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc.22,032$0 M—0.01%+17%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC13,687$0 M—0.03%+66%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation13,600$0 M—0.02%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.10,724$0 M—0.02%+5.2%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,238$0 M—<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors9,357$0 M—<0.01%+1.0%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC13,567$0 M—<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC9,241$0 M—0.01%−22%Jun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.13,916$0 M—<0.01%newMay 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.13,000$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.8,029$0 M—<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.7,100$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC10,145$0 M—0.02%+14%Jul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC6,809$0 M—0.09%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC6,754$0 M—0.02%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.10,088$0 M—0.01%+2520%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC6,221$0 M—0.02%+19%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,660$0 M—<0.01%+125%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company8,504$0 M—0.01%newMay 31, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc.8,264$0 M—<0.01%+21%May 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.5,193$0 M—0.04%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.7,607$0 M—0.01%+5986%May 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC4,864$0 M—0.09%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,668$0 M—0.01%−30%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,597$0 M—0.02%+18%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC4,392$0 M—0.02%+15%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC4,229$0 M—<0.01%+1.8%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,333$0 M—0.02%+16%Jun 30, 2026
🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc.5,175$0 M—<0.01%+16%May 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC3,288$0 M—<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,236$0 M—0.02%+39%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC3,140$0 M—<0.01%newJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,500$0 M—<0.01%newMay 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,887$0 M—0.02%+19%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,598$0 M—0.02%+38%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,667$0 M—0.01%newJul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC3,540$0 M—<0.01%no changeJul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,148$0 M—0.01%+53%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,974$0 M—<0.01%+1.8%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,925$0 M—0.02%+14%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC2,403$0 M—<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,275$0 M—0.01%+1.6%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,551$0 M—0.02%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,473$0 M—0.02%+30%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,903$0 M—0.02%+19%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,285$0 M—0.03%+72%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,734$0 M—<0.01%+2377%May 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,057$0 M—<0.01%−26%Jun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,010$0 M—<0.01%−30%Jun 30, 2026
🇺🇸 T. Rowe Price Moderate Allocation PortfolioT. Rowe Price Associates, Inc.912$0 M—0.01%+3.2%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC869$0 M—<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,260$0 M—<0.01%+73%Jul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC819$0 M—<0.01%+32%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC968$0 M—0.01%newMay 31, 2026
🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors904$0 M—<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC554$0 M—0.01%+2.0%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC769$0 M—<0.01%newMay 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC757$0 M—<0.01%newMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.488$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC480$0 M—<0.01%+34%Jun 30, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC404$0 M—<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC567$0 M—<0.01%+58%Jul 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC488$0 M—<0.01%−92%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors76$0 M—<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.61$0 M—<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 95 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Aktis Oncology, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$79.3 M
9 purchases, 6 insiders
Sold, 12 months
$3.2 M
11 sales, 3 insiders
Net, 12 months
$76.0 M
open market only
Insiders on file
10
since
$79.3 M-$3.0 M$0Jan 2026: bought $79.3 M (9 trades), sold $0 (0 trades)Jan 26Jul 2026: bought $0 (0 trades), sold $3.0 M (9 trades)JulSep 2026: bought $0 (0 trades), sold $259 K (2 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Aktis Oncology, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Akos CzibereChief Medical OfficerOption exercise10b5-1 plan+12,500$4.950$62 K12,500Form 4
filed Akos CzibereChief Medical OfficerSell10b5-1 plan-5,099$20.19$103 K7,401Form 4
filed Akos CzibereChief Medical OfficerSell10b5-1 plan-7,401$21.03$156 K0Form 4
filed Ken HerrmannDirectorOption exercise+3,506$0.080—3,506Form 4
filed Ken HerrmannDirectorOption exercise+1,350$1.910$3 K4,856Form 4
filed Ken HerrmannDirectorSell-3,506$24.56$86 K1,350Form 4
filed Ken HerrmannDirectorSell-1,350$24.56$33 K0Form 4
filed Ken HerrmannDirectorOption exercise+3,065$0.080—3,065Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Aktis Oncology, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

IPO: priced at $18.00, raising $317.7M · IPO calendar

Stock splits: 1-for-3.8 reverse split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Aktis Oncology, Inc. scorecard#

Passes 1 of the 1 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.37 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Aktis Oncology, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Bylaws or fiscal year changed 1 · Results announced 4

Aktis Oncology, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Aktis Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$175 MNo. 1$50 to $250 million39equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Aktis Oncology, Inc.#

2 labor condition applications certified in fiscal 2024 for 2 positions, at a median wage of $125 K a year.

Certified, FY2024
2
#1,657 among companies on value.today
Worker positions
2
Median wage offered
$125 K
a year, full-time
Applications filed
2
Aktis Oncology, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Associate Scientist, Lead DiscoveryMolecular and Cellular Biologists1$94 K
Principal Scientist, Oncology ResearchBiochemists and Biophysicists1$155 K

Where: Boston, MA 2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aktis Oncology, Inc.

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Aktis Oncology, Inc.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 5, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Aktis Oncology, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Aktis Oncology, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Aktis Oncology, Inc.? Suggest a correction